Home » Newsletters » BioWorld Science

BioWorld Science

Aug. 28, 2013

View Archived Issues

Results presented for nanoliposomal irinotecan for the treatment of metastatic pancreatic cancer

The development of an optogenetic two-hybrid system for the control of mammalian gene transcription

Nuclear imaging of a novel radiolabeled probe for prostate cancer

Phase I study of GNX-5086 enrolls first healthy volunteer

Japanese researchers present new AMPA receptor modulators

Sareum Holdings patents novel agents for cancer

New cathepsin S and/or L inhibitors synthesized at Roche

Novel Der p 23 peptide-derived immunotherapy for house dust mite allergy

Researchers in China prepare new agents for HIV infection

Scientists in Germany disclose new agents for bacterial infections

Dainippon Sumitomo Pharma designs novel coagulation factor inhibitors

Subcutaneous Orencia launched in Japan for rheumatoid arthritis

Agenix and Arrayjet to jointly develop point-of-care diagnostic test

Spartan RX CYP2C19 assay receives FDA 510(k) clearance

Mount Sinai receives research grant for autism subtype study

BiondVax reports altered prime-boost strategy for its influenza vaccine

Orexigen receives DMC clearance to conduct interim analysis for the Light Study

OncoGenex reports Rainier trial initiation

Virttu Biologics treats first cohort in phase I/II mesothelioma study

Catalyst obtains FDA breakthrough therapy designation for Firdapse

Epilepsy treatment to be launched in Japan for partial-onset seizures

Health Canada approves Roche's Erivedge for advanced basal cell carcinoma

QRxPharma set to resubmit MoxDuo NDA

Medivir reports interim results from cohort 2 of COSMOS study

Bharat Biotech launches Typbar-TCV typhoid conjugate vaccine

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...